DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.

The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...

DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...

Despite these, DexCom's share repurchase program significantly reduced outstanding shares, arguably supporting its share price. Though the company's earnings growth of 18.1% annually over five ...

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

DexCom DXCM-2.10%decrease; red down pointing triangle received a warning letter from the Food and Drug Administration ...

Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...